INI Study

INI Study: The Study Of Nasal Insulin To Fight Forgetfulness (SNIFF)

Condition/Disease: Alzheimer’s

Lead Researcher: Aimee L. Pierce, MD

Location: UCI Campus (UCI MIND Gottschalk Medical Plaza, ICTS in Hewitt Hall, Newport Diagnostic Center)

Purpose: To evaluate whether insulin, when administered as a nasal spray, improves memory in adults amnestic mild cognitive impairment (aMCI) or early Alzheimer’s disease (AD).

Eligibility: Male and female participants, ages 55-85 years old and diagnosed with aMCI or AD

Time Commitment: 18 months total: treatment phase (twice daily intake of nasal insulin or placebo for 12 months), open label phase (twice daily intake of nasal insulin for 6 months)

Benefits: There is no guarantee of personal benefit from participating in this research study.  All subjects will receive active study drug for a period of 6 months during the open label phase.  Subjects will also receive their blood test results which may reveal more information about their blood sugar, cholesterol, liver function and other related health information.

Compensation: Participants are eligible to receive the following compensation in cash during the course of this study:

  • $25 for each study visit; there are 8 visits ($200 max).
  • $100 for each completed lumbar puncture; there are two lumbar punctures ($200 max).

The grand total compensation for this study is a maximum of $400 in cash.

Phone: 949-824-6187

Click here to view flyer.